Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan/Cisplatin vs Docetaxel/Cisplatin in Advanced NSCLC
NCT00263016Phase 2Terminated
- Sponsor
- Sanofi
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Sanofi. Primary endpoints: Tumour response rate and Survival at 1 year. Started May 2005; status: terminated.
02
Drugs
irinotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00263016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263016.